BACIL PHARMA LTD.

Bacil Pharma Limited's Board of Directors has approved a proposal to raise up to ₹50 crores through various permissible modes, including Rights Issue, Preferential Issue, or convertible securities. The board has authorized the Managing Director, CFO, and Company Secretary to explore fund-raising options, appoint intermediaries, and finalize the structure. The specific mode, size, pricing, and terms will be determined later, subject to regulatory and shareholder approvals. The meeting was held on June 26, 2026, from 4 PM to 6 PM.

Bacil Pharma Ltd has announced the closure of its trading window for designated persons, effective July 1, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will reopen 48 hours after the conclusion of the Board of Directors' meeting, which is scheduled to consider the un-audited financial results for the quarter ended June 30, 2026. The exact date of the board meeting will be communicated separately to the stock exchanges.

Manubhai Amrutlal Shah has disclosed the disposal of 3,94,893 shares in Bacil Pharma Limited, representing 2.75% of the total share capital. The transactions occurred on June 23rd and 24th, 2026, via open market operations. Following this disposal, Mr. Shah's shareholding in Bacil Pharma has reduced from 12.77% to 10.02%. The total equity share capital of the company remains unchanged at 1,43,53,000 equity shares of Rs. 10/- each.

Nikita Hiren Patel has disclosed the disposal of 10,19,052 equity shares, representing 7.10% of the total share capital, in Bacil Pharma Limited. The transactions occurred on June 22nd and 23rd, 2026, via open market operations. Prior to this sale, Ms. Patel held 17.17% of the company's shares. Following the disposal, her shareholding has reduced to 14,44,844 shares, constituting 10.07% of the total equity. The total equity share capital of Bacil Pharma remains at 1,43,53,000 equity shares of Rs. 10/- each.

Bacil Pharma Ltd has announced that its Board of Directors will convene on June 26, 2026, to discuss and approve proposals for raising funds. The company is exploring various permissible modes, including Preferential Issue, Rights Issue, or a combination thereof, subject to regulatory approvals. The meeting agenda also includes transacting any other business with the Chairman's permission. Concurrently, the trading window for designated persons and their relatives will be closed from today until 48 hours after the board meeting's outcome is declared, in line with SEBI's insider trading regulations.

Bacil Pharma Limited announced its intention to establish a new wholly-owned subsidiary, "Bacil Research & Development Private Limited". This move is subject to regulatory approvals. The subsidiary's primary objective will be to conduct research and development activities, along with other allied business functions permitted by law. This strategic initiative aims to bolster the company's innovation pipeline and future growth prospects.

Manubhai Amrutlal Shah has disposed of 8,00,000 equity shares, representing 5.57% of the total share capital, in Bacil Pharma Ltd. This transaction occurred on June 10, 2026, via open market transfer. Following the disposal, Mr. Shah's shareholding in the company has reduced from 18.34% to 12.77%. The total equity share capital of Bacil Pharma remains at 1,43,53,000 equity shares of Rs. 10 each.

Nikita Patel has disclosed the disposal of 3,26,104 equity shares, representing 2.27% of the total share capital, in Bacil Pharma Limited. The transactions occurred off-market on June 8th and 9th, 2026. Following this disposal, Nikita Patel's total shareholding in Bacil Pharma has reduced to 17.17% (24,63,896 shares). The total equity share capital of the company remains at 1,43,53,000 equity shares.

Bacil Pharma Ltd confirms that Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning the statement of deviation or variation in fund utilization, is not applicable to the company for the quarter ended March 31, 2026. The company clarifies that it did not raise any funds through Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement (QIP), or any other issue during the specified quarter.

Bacil Pharma Ltd's board meeting on May 22, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The meeting, which commenced at 05:00 P.M. and concluded at 08:00 P.M., also included a review of other business activities. The balance sheet shows total assets of ₹2739.26 Lacs as of March 31, 2026, compared to ₹2560.02 Lacs in the previous year. Equity Share capital remained at ₹1397.02 Lacs.